Abstract
In order to identify proteins that bind to the PDZ domain of Erbin, we tested the C-termini of several proteins in a yeast two-hybrid assay. ErbB2, APC, β-catenin, c-Rel and HTLV-1 Tax were identified as ligands of the PDZ domain of Erbin. The interactions were verified by co-immunoprecipitation experiments. These findings demonstrate the promiscuity of the PDZ domain of Erbin.
Keywords: Erbin, PDZ domain, ErbB2, APC, c-Rel, HTLV-1 Tax
Protein & Peptide Letters
Title: Interaction Partners of the PDZ Domain of Erbin
Volume: 13 Issue: 9
Author(s): Angelika Ress and Karin Moelling
Affiliation:
Keywords: Erbin, PDZ domain, ErbB2, APC, c-Rel, HTLV-1 Tax
Abstract: In order to identify proteins that bind to the PDZ domain of Erbin, we tested the C-termini of several proteins in a yeast two-hybrid assay. ErbB2, APC, β-catenin, c-Rel and HTLV-1 Tax were identified as ligands of the PDZ domain of Erbin. The interactions were verified by co-immunoprecipitation experiments. These findings demonstrate the promiscuity of the PDZ domain of Erbin.
Export Options
About this article
Cite this article as:
Ress Angelika and Moelling Karin, Interaction Partners of the PDZ Domain of Erbin, Protein & Peptide Letters 2006; 13 (9) . https://dx.doi.org/10.2174/092986606778256126
DOI https://dx.doi.org/10.2174/092986606778256126 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Current Drug Safety Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination
Current Topics in Medicinal Chemistry Correlation between Cancer Antigen 15.3 Value and Qualitative and Semiquantitative Parameters of Positron Emission Tomography/Computed Tomography in Breast Cancer Patients
Current Radiopharmaceuticals Expeditious Entry to Functionalized Pseudo-peptidic Organoselenide Redox Modulators via Sequential Ugi/SN Methodology
Anti-Cancer Agents in Medicinal Chemistry Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Cytotoxicity and Cell Death Mechanisms Induced by a Novel Bisnaphthalimidopropyl Derivative against the NCI-H460 non-small Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Use of Cytokines in Cancer Vaccines/Immunotherapy: Recent Developments Improve Survival Rates for Patients with Metastatic Malignancy
Current Pharmaceutical Design Synthesis and Antiproliferative Activity of Coumarin-Estrogen Conjugates against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Menthol – Pharmacology of an Important Naturally Medicinal “Cool”
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance
Current Cancer Drug Targets Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design